[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 10
2. Dokmak S, Cabral C, Couvelard A, Aussilhou B, Belghiti J, Sauvanet A: Pancreatic metastasis from nephroblastoma: an unusual entity. JOP; 2009;10(4):396-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Pancreatic metastasis from renal cell carcinoma is a well-known entity.
  • A nephroblastoma is a frequent childhood cancer but can also occur in adults.
  • After resection, the patient received adjuvant high dose chemotherapy with autologous hematopoietic stem-cell support.
  • After a 21-month follow-up, the patient was in good general condition but had liver recurrence without intra-pancreatic recurrence.
  • A nephroblastoma, like clear cell renal carcinoma, can be considered a possible etiology of pancreatic metastasis from a primary renal tumor.
  • [MeSH-major] Kidney Neoplasms / pathology. Pancreatic Neoplasms / secondary. Wilms Tumor / pathology
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy / methods. Humans. Male. Pancreaticoduodenectomy / methods. Treatment Outcome. Young Adult


3. Reingruber B, Boettcher MI, Klein P, Hohenberger W, Pelz JO: Hyperthermic intraperitoneal chemoperfusion is an option for treatment of peritoneal carcinomatosis in children. J Pediatr Surg; 2007 Sep;42(9):E17-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Gastrointestinal carcinomas in childhood are rare and frequently present at an advanced stage.
  • METHODS: After treating a series of adult patients, HIPEC for peritoneal carcinomatosis from a signet cell carcinoma of the colon was performed intraoperatively in a 12-year-old boy.
  • We performed intraoperative drug level monitoring and daily postoperative liver and kidney function tests and differential blood counts.
  • Perfusate and venous drug levels were similar to those in an adult case.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / secondary. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Mitomycin / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary

  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848227.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


Advertisement
4. Sun X, Niu G, Yan Y, Yang M, Chen K, Ma Y, Chan N, Shen B, Chen X: Phage display-derived peptides for osteosarcoma imaging. Clin Cancer Res; 2010 Aug 15;16(16):4268-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Osteosarcoma represents the most common malignant primary bone tumor in childhood; however, the survival rate has remained unchanged for the past 20 years.
  • To improve existing diagnosis and treatment methods and broaden the spectrum of imaging agents that can be used for early detection and assessment of tumor response to therapy, we performed a phage display-based screening for peptide sequences that bind specifically to osteosarcoma cells.
  • -12 phage display peptide library composed of 2.7 x 10(9) different displayed peptides, one peptide was enriched after four rounds of in vitro selection in 143B osteosarcoma tumor cells with 293T human embryonic kidney cells as a control.
  • Both the peptide and the phage clone displaying the peptide were conjugated with fluorescent dyes for in vitro cell and ex vivo tumor tissue stainings.
  • The peptide was further labeled with (18)F for positron emission tomography imaging studies.
  • Cell uptake and efflux and ex vivo biodistribution were also done with (18)F-labeled osteosarcoma specific peptide.
  • The fluorescence staining showed that FITC-OSP-1-phage or Cy5.5-OSP-1 had high binding with a panel of osteosarcoma cell lines, much less binding with UM-SCC1 human head and neck squamous cell carcinoma cells, and almost no binding with 293T cells, whereas the scrambled peptide OSP-S had virtually no binding to all the cell lines. (18)F-OSP-1 had significantly higher accumulation in 143B tumor cells both in vitro and in vivo than (18)F-OSP-S. (18)F-OSP-1 also had higher uptake in 143B tumors than in UM-SCC-1 tumors.
  • [MeSH-major] Bone Neoplasms / diagnosis. Diagnostic Imaging / methods. Osteosarcoma / diagnosis. Peptide Library. Peptides
  • [MeSH-minor] Animals. Female. Humans. Mice. Mice, Nude

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2003 Mar 1;17(5):545-80 [12629038.001]
  • [Cites] Mol Imaging Biol. 2010 Oct;12(5):530-8 [19949981.001]
  • [Cites] Pediatr Hematol Oncol. 2005 Jun;22(4):335-43 [16020121.001]
  • [Cites] J Cell Biochem. 2005 Dec 1;96(5):897-905 [16149080.001]
  • [Cites] Neoplasia. 2006 Dec;8(12):1011-8 [17217618.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Feb;7(2):169-81 [17288528.001]
  • [Cites] Biochem Soc Trans. 2007 Aug;35(Pt 4):780-3 [17635147.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2119-52 [17939129.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):526-36 [19147566.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:887-99 [19273106.001]
  • [Cites] Methods Mol Biol. 2009;512:355-63 [19347288.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1483-94 [19360404.001]
  • [Cites] Curr Cancer Drug Targets. 2009 Nov;9(7):843-53 [20025572.001]
  • [Cites] Cell Mol Life Sci. 2010 Mar;67(5):749-67 [20196239.001]
  • [Cites] Protein Eng Des Sel. 2010 Jun;23(6):423-30 [20185523.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1524-8 [7509076.001]
  • (PMID = 20570932.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZII EB000066-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Library; 0 / Peptides
  • [Other-IDs] NLM/ NIHMS216996; NLM/ PMC2921467
  •  go-up   go-down


5. Houghton PJ: Everolimus. Clin Cancer Res; 2010 Mar 01;16(5):1368-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Food and Drug Administration for treatment of renal cell carcinoma (RCC) refractory to inhibitors of vascular endothelial growth factor (VEGF) receptor signaling.
  • Although the target for everolimus, [the serine-threonine kinase mammalian target of rapamycin (mTOR)] is well established, the mechanism by which this agent retards tumor growth is not well defined.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Sirolimus / analogs & derivatives
  • [MeSH-minor] Animals. Clinical Trials as Topic. Everolimus. Humans

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):596-603 [16226444.001]
  • [Cites] Leuk Lymphoma. 2009 Dec;50(12):1916-30 [19757306.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):153-5 [16530700.001]
  • [Cites] Genes Dev. 2008 Jan 15;22(2):239-51 [18198340.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1603-10 [18332469.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13907-17 [11847216.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29655-60 [12777372.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):335-48 [15122205.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3500-7 [15150104.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):519-23 [15193254.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):91-9 [15261145.001]
  • [Cites] Genes Dev. 2004 Dec 1;18(23):2893-904 [15545625.001]
  • [Cites] Nature. 2005 Feb 3;433(7025):477-80 [15690031.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8204-9 [15928081.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1588-95 [18332470.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Clin Cancer Res. 2009 Mar 1;15(5):1612-22 [19223496.001]
  • [Cites] Mol Cancer Ther. 2009 Apr;8(4):742-53 [19372546.001]
  • [Cites] Ann Oncol. 2009 Oct;20(10):1674-81 [19549709.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7662-71 [19789339.001]
  • [Cites] J Clin Oncol. 2009 Sep 20;27(27):4536-41 [19687332.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • (PMID = 20179227.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077776; United States / NCI NIH HHS / CA / CA23099; United States / NCI NIH HHS / CM / N01 CM042216; United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / P01 CA023099-310011; United States / NCI NIH HHS / CA / CA77776; United States / NCI NIH HHS / CA / R01 CA077776-11
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9HW64Q8G6G / Everolimus; W36ZG6FT64 / Sirolimus
  • [Number-of-references] 23
  • [Other-IDs] NLM/ NIHMS167833; NLM/ PMC3003868
  •  go-up   go-down


6. Sastry J, Kellie SJ: Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol; 2005 Jul-Aug;22(5):441-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cisplatin in higher doses have been used routinely in the treatment of childhood tumours including neuroblastoma and germ cell tumors.
  • Food and Drug Administration for use in patients receiving cisplatin.
  • The authors report a case of severe toxicity with cisplatin in a girl with epithelial cell carcinoma of the ovary despite the use of amifostine.
  • [MeSH-major] Amifostine / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma / drug therapy. Cisplatin / adverse effects. Hearing / drug effects. Kidney / drug effects. Nervous System / drug effects. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Drug Administration Schedule. Fatal Outcome. Female. Humans. Injections, Intravenous. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020136.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] M487QF2F4V / Amifostine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, Collins MH: Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer; 2008 Apr 1;112(7):1607-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation renal cell carcinoma: lack of negative impact due to lymph node spread.
  • BACKGROUND: Pediatric renal cell carcinoma (RCC) is clinically distinct from adult RCC.
  • Characterization of the unique biological and clinical features of pediatric RCC are required.
  • METHODS: A retrospective review and biological analysis of all RCC cases presenting to Cincinnati Children's Hospital Medical Center (CCHMC) in the last 30 years was undertaken.
  • A literature review of pediatric TFE+ cases was performed.
  • RESULTS: Eleven cases of RCC with clinical data were identified in our institutional review as follows: 6 clear cell, 2 papillary, 2 translocation, and 1 sarcomatoid.
  • Seven of 8 TFE+ RCC patients presented with TNM Stage III/IV disease.
  • Literature analysis confirmed a significant increase in advanced stage presentation in pediatric TFE+ RCC compared with TFE- RCC.
  • Fourteen of fifteen (93.3%) patients with TFE+ stage III/IV RCC due to lymph node spread (N+ M(0)) remain disease free with a median and mean follow-up of 4.4 and 6.3 years, respectively (range, 0.3-15.5).
  • CONCLUSIONS: Translocation morphology RCC is the predominant form of pediatric RCC, associated with an advanced stage at presentation.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology. Lymph Nodes / pathology. Translocation, Genetic
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / secondary. Adolescent. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Leucine Zippers. Lymphatic Metastasis. Male. Microphthalmia-Associated Transcription Factor / genetics. Neoplasm Proteins / genetics. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278810.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / MITF protein, human; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins; 0 / TFE3 protein, human; 0 / TFEB protein, human
  •  go-up   go-down


9. Shnorhavorian M, Friedman DL, Koyle MA: Genitourinary long-term outcomes for childhood cancer survivors. Curr Urol Rep; 2009 Mar;10(2):134-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genitourinary long-term outcomes for childhood cancer survivors.
  • The treatment of pediatric malignancies represents one of the success stories of modern medicine.
  • There continue to be late toxicities and secondary malignancies of the genitourinary (GU) system for childhood cancer survivors related to the specific therapeutic exposures.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Neoplasms, Second Primary / epidemiology. Urinary Tract / drug effects. Urogenital Neoplasms / epidemiology
  • [MeSH-minor] Carcinoma, Renal Cell / drug therapy. Child. Disease-Free Survival. Dose-Response Relationship, Drug. Health Status. Humans. Kidney Neoplasms / drug therapy. Quality of Life. Radiotherapy Dosage. Survivors. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jul;15(1):99-104 [2968967.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2795-800 [2025844.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1837-44 [2015407.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):668-73 [15390293.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Arch Dis Child. 2003 Jun;88(6):493-6 [12765914.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1926-34 [11283124.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):159-65 [8270973.001]
  • [Cites] Nephrol Dial Transplant. 1999 Jun;14(6):1441-4 [10383005.001]
  • [Cites] Cancer. 1988 Feb 1;61(3):451-7 [3338015.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):1000-3 [7947075.001]
  • [Cites] Am J Nephrol. 1994;14(2):81-4 [8080010.001]
  • [Cites] J Pediatr Oncol Nurs. 1991 Apr;8(2):59 [1675067.001]
  • [Cites] Med Pediatr Oncol. 1997 Jan;28(1):35-40 [8950334.001]
  • [Cites] J Pediatr. 1985 Apr;106(4):659-63 [2984399.001]
  • [Cites] Am J Clin Oncol. 1998 Feb;21(1):58-63 [9499259.001]
  • [Cites] Cancer. 1987 May 1;59(9):1577-81 [3470110.001]
  • [Cites] J Urol. 2001 Oct;166(4):1455-8 [11547111.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Pediatr Blood Cancer. 2004 Mar;42(3):289-91 [14752871.001]
  • [Cites] Pediatr Nephrol. 1999 Feb;13(2):153-62 [10229006.001]
  • [Cites] N Engl J Med. 1988 Apr 21;318(16):1028-32 [3352696.001]
  • [Cites] J Clin Pharmacol. 1999 May;39(5):454-61 [10234592.001]
  • [Cites] Med Pediatr Oncol. 2003 Sep;41(3):190-7 [12868118.001]
  • [Cites] Pediatr Nephrol. 2001 Oct;16(10):796-9 [11605785.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):594-8 [17514733.001]
  • [Cites] Pediatr Blood Cancer. 2004 May;42(5):427-32 [15049014.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2506-13 [12011129.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):295-300 [2056973.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):173-90 [8418231.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;23(2):121-2 [2910509.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1228-32 [16682132.001]
  • [Cites] J Urol. 2005 Nov;174(5):1972-5 [16217371.001]
  • [Cites] Br J Cancer. 1998 May;77(10):1677-82 [9635848.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1851-9 [7636528.001]
  • [Cites] J Pediatr Oncol Nurs. 2008 Mar-Apr;25(2):97-101 [18353752.001]
  • (PMID = 19239818.001).
  • [ISSN] 1534-6285
  • [Journal-full-title] Current urology reports
  • [ISO-abbreviation] Curr Urol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 37
  •  go-up   go-down


10. Spreafico F, Collini P, Terenziani M, Marchianò A, Piva L: Renal cell carcinoma in children and adolescents. Expert Rev Anticancer Ther; 2010 Dec;10(12):1967-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma in children and adolescents.
  • Although rare in children and adolescents, renal cell carcinomas (RCCs) raise important questions concerning the best treatment approach and accurate pathologic classification.
  • The differences emerging between childhood and adulthood RCC probably prevent any direct generalized application of therapies to children that are validated for adults.
  • The translocation type of RCC, which forms a distinct category characterized by translocations involving Xp11.2 or, less frequently, 6p21, has recently emerged as the predominant type of RCC in children and adolescents, whereas it is rarely diagnosed in adults.
  • Nephron-sparing surgery is currently recommended in adults for selected small-volume tumors, but additional data are needed before this experience can be extensively transferred to the pediatric population.
  • The backbone of systemic therapies for adult RCC has recently been changed by the introduction of drugs designed to target tumor-related angiogenesis and signal transduction.
  • It is worth noting that the largest clinical efficacy trials on targeted molecules have been conducted on clear-cell RCC.
  • While targeted drugs have become the standard of care for adult metastatic RCC, there are currently no published reports on their role in children, and their use should be considered for patients with unresectable metastatic or advanced-stage RCC.
  • [MeSH-major] Carcinoma, Renal Cell / therapy. Kidney Neoplasms / therapy. Nephrectomy / methods
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Agents / pharmacology. Child. Drug Delivery Systems. Humans. Lymph Node Excision / methods. Nephrons / surgery

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21110762.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement